LY 97119 | 72456-59-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: LY 97119
• 英文别名: N-(4-(4-chlorophenyl)butyl)-N-ethylheptan-1-amine；N-ethyl-N-n-heptyl-4-(4-chlorophenyl)butylamine；Benzenebutanamine, 4-chloro-N-ethyl-N-heptyl-；N-[4-(4-chlorophenyl)butyl]-N-ethylheptan-1-amine
• CAS: 72456-59-8
• 化学式: C₁₉H₃₂ClN
• 分子量: 309.923
• InChiKey: XRXXKWOKXISVCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  21
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  溴乙烷 、 LY 97119 生成 N,N-diethyl-N-n-heptyl-4-(4-chlorophenyl)butylammonium bromide
  参考文献：
  名称：

  Quaternary ammonium antiarrhythmic drugs

  摘要：

  某些苯丁胺的季铵盐是有用的抗心律失常药物。提供了一种治疗心律失常并延长心脏组织动作电位的方法。披露了含有这种季铵盐的药物配方。

  公开号：

  US04289787A1
• 作为产物：
  描述：

  3-(4-氯苯甲酰)丙酸 在 硫酸 、 三乙酰氧基硼氢化钠 、 二异丁基氢化铝 、 一水合肼 、 calcium chloride 、 potassium hydroxide 作用下， 以 二氯甲烷 、 水 、 1,2-二氯乙烷 、 甲苯 、 二乙二醇 为溶剂， 反应 5.0h， 生成 LY 97119
  参考文献：
  名称：

  Removal of Human Ether-à-go-go Related Gene (hERG) K⁺ Channel Affinity through Rigidity: A Case of Clofilium Analogues

  摘要：

  Cardiotoxicity is a side effect that plagues modern drug design and is very often due to the off-target blockade of the human ether-a-go-go related gene (hERG) potassium channel. To better understand the structural determinants of this blockade, we designed and synthesized a series of 40 derivatives of clofilium, a class III antiarrhythrnic agent. These were evaluated in radioligand binding and patch-damp assays to establish structure affinity relationships (SAR) for this potassium channel. Efforts were especially focused on studying the influence of the structural rigidity and the nature of the linkers composing the clofilium scaffold. It was shown that introducing triple bonds and oxygen atoms in the n-butyl linker of the molecule greatly reduced affinity without significantly modifying the pK(a) of the essential basic nitrogen. These findings could prove useful in the first stages of drug discovery as a systematic way of reducing the risk of hERG K+ channel blockade-induced cardiotoxicity.

  DOI：

  10.1021/jm4010434

文献信息

• 1,4‐Aminoarylation of Butadienes via Photoinduced Palladium Catalysis
  作者：Yuan Cai、Gaurav Gaurav、Tobias Ritter

  DOI：10.1002/anie.202311250

  日期：2024.4.2

  Utilizing readily available and cost-effective aryl halides, amines, and butadienes as starting materials, in conjunction with rac-BINAP and a Pd catalyst, we can efficiently synthesize highly valuable complex allylamines through a rapid one-step process enabled by photocatalysis.

  利用容易获得且具有成本效益的芳基卤化物、胺和丁二烯作为起始原料，结合rac -BINAP和Pd催化剂，我们可以通过光催化的快速一步法有效合成高价值的复杂烯丙胺。
• Quaternary ammonium salts, and their formulations and preparation
  申请人：ELI LILLY AND COMPANY

  公开号：EP0002604B1

  公开（公告）日：1983-05-04
• US4289787A
  申请人：——

  公开号：US4289787A

  公开（公告）日：1981-09-15
• US4395410A
  申请人：——

  公开号：US4395410A

  公开（公告）日：1983-07-26
• Removal of Human Ether-à-go-go Related Gene (hERG) K⁺ Channel Affinity through Rigidity: A Case of Clofilium Analogues
  作者：Julien Louvel、João F. S. Carvalho、Zhiyi Yu、Marjolein Soethoudt、Eelke B. Lenselink、Elisabeth Klaasse、Johannes Brussee、Adriaan P. IJzerman

  DOI：10.1021/jm4010434

  日期：2013.12.12

  Cardiotoxicity is a side effect that plagues modern drug design and is very often due to the off-target blockade of the human ether-a-go-go related gene (hERG) potassium channel. To better understand the structural determinants of this blockade, we designed and synthesized a series of 40 derivatives of clofilium, a class III antiarrhythrnic agent. These were evaluated in radioligand binding and patch-damp assays to establish structure affinity relationships (SAR) for this potassium channel. Efforts were especially focused on studying the influence of the structural rigidity and the nature of the linkers composing the clofilium scaffold. It was shown that introducing triple bonds and oxygen atoms in the n-butyl linker of the molecule greatly reduced affinity without significantly modifying the pK(a) of the essential basic nitrogen. These findings could prove useful in the first stages of drug discovery as a systematic way of reducing the risk of hERG K+ channel blockade-induced cardiotoxicity.